The company said, “The Company continues to expect full year 2024 total sepsis product revenue of $10.0 million to $11.0 million, representing growth of 49% to 64%, compared to $6.7 million in 2023. The Company’s 2024 revenue guidance consists entirely of sepsis product revenue and does not include potential sales of the T2Biothreat Panel or the T2Lyme Panel.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TTOO:
- T2 Biosystems Announces Second Quarter 2024 Financial Results
- T2 Biosystems Announces Commercial Expansion Through Malaysia and Indonesia Distributor
- TTOO Upcoming Earnings Report: What to Expect?
- T2 Biosystems to Report Second Quarter 2024 Financial Results and Business Updates on July 29, 2024
- T2 Biosystems files $150M mixed securities shelf